Amgen (BUE:AMGN) FFO


BUE:AMGN Amgen Inc BUE:AMGN
83 GF Score
Price ARS18,660.00
GF Value ARS18,297.72
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Amgen FFO?

FFO (Funds from operations) only applies to REITs.

BUE:AMGN
83GF Score
Amgen Inc BUE:AMGN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Amgen (BUE:AMGN) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of ARS18,660.00 is trading 2% above its estimated GF Value™ of ARS18,297.72. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for BUE:AMGN:

  • FFO:
  • GF Value™: ARS18,297.72 vs. price of ARS18,660.00 (2% above fair value)
  • GF Score™: 83/100 with 8 warning signs

No single metric tells the full story. See the BUE:AMGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
83GF Score

Get the complete analysis for BUE:AMGN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS18,660.00
Price
ARS18,297.72
GF Value